Evidence record · ER-CJC1295-BODYCOMP-006
Does CJC-1295 build muscle or reduce fat?
CJC-1295 builds muscle or reduces body fat
CJC-1295 has not been shown in dependable human outcome trials to build muscle or reduce body fat. Small pharmacology studies show that a defined long-acting formulation can raise growth hormone and IGF-1, but a hormone change is not proof of improved body composition, strength or function.
Claim boundary
What this verdict covers
The claim requires measured change in lean mass, fat mass, strength or function over meaningful follow-up. Short-term GH or IGF-1 concentrations are surrogate signals, not the target outcomes.
- Compound
- CJC-1295
- Population
- Adults seeking body-composition change
- Outcome
- Lean mass, fat mass or function
- Record ID
- ER-CJC1295-BODYCOMP-006
Evidence synthesis
What the research can support
Available human CJC-1295 publications focus on pharmacokinetics and hormone responses. They were not designed or powered to establish muscle gain, fat loss, athletic performance or durable functional improvement.
Why the confidence is very low
No suitable controlled human body-composition programme was identified. Long-term endocrine, metabolic and cardiovascular risks are not resolved for non-medical use.
Decision boundary
What this record cannot tell you
This record cannot identify the contents, strength, purity, sterility or stability of a particular vial. It does not provide a dosing plan, administration instructions or a personal treatment recommendation. A supported narrow outcome cannot be transferred to a different route, population or product.
This publication has not independently tested a product for this record. Product evidence belongs to a named batch and method; clinical evidence belongs to the intervention actually studied.
From our work: how we checked this claim
ER-CJC1295-BODYCOMP-006 addresses one bounded question: Does CJC-1295 build muscle or reduce fat?. Yianni Kiromitis checked the search record, source descriptions, study design, population, intervention identity, comparator and patient-important outcomes against the published evidence method. The source ledger contains 3 primary or official sources. Each was assigned only the proposition it can support; a regulatory document was not treated as a treatment trial, and an animal or laboratory finding was not presented as a dependable human outcome.
The recorded evidence basis is No reliable evidence, the verdict is Insufficient and confidence is Very low. Eleni Kiromitis reviewed study design, biomedical evidence, laboratory context and analytical limits. Dr Stavroula Nikitopoulou reviewed the clinical claim, adverse effects, contraindications, red flags and patient-facing safety wording. Both completed their assigned review on 10 August 2026. Yianni retained publication and correction responsibility. The review notes identify which source supports each material claim and which limitation must remain beside the conclusion.
No direct product testing, seller data, personal treatment experience or patient experience was used to set this verdict. The record cannot establish the contents, strength, purity, sterility or stability of a particular vial, and it does not provide dosing, administration or personalised treatment advice. A finding cannot be transferred to a different route, population, product or outcome without new evidence. We also checked the visible review date against the publication record and structured data. A new controlled study, regulator update, corrected source, analytical report or credible safety signal can trigger reassessment through the public correction route.
Source ledger
Evidence used for this verdict
Each source supports only the proposition stated beside it. Regulatory scope and study scope remain visible.
| Source | What it establishes | What it does not establish | Checked |
|---|---|---|---|
| Human CJC-1295 pharmacology study | CJC-1295 produced sustained hormone responses in the tested setting. | Hormone response is not evidence of muscle gain or fat loss. | 10 August 2026 |
| Repeated-dose CJC-1295 study | The study describes pharmacodynamic effects after repeated exposure. | It did not establish patient-important body-composition outcomes. | 10 August 2026 |
| FDA bulk-substance safety page | FDA identifies unresolved safety concerns for CJC-1295-related compounded substances. | It does not quantify long-term risk for a specific vial. | 10 August 2026 |
Quick answers
Frequently asked questions
What is the verdict on CJC-1295 for this claim?
The verdict is insufficient for the precise claim stated on this page. It combines the evidence type, directness, consistency and study limits; it is not a rating of the compound as a whole. The confidence field shows how readily new evidence could change the conclusion.
What evidence supports this verdict?
Available human CJC-1295 publications focus on pharmacokinetics and hormone responses. They were not designed or powered to establish muscle gain, fat loss, athletic performance or durable functional improvement. The source ledger below links the primary or regulatory records used and states what each source cannot establish.
Does this evidence apply to a peptide vial sold online?
No. A study or authorisation applies to the exact material, formulation, route, population and controls that were evaluated. It cannot verify the identity, amount, purity, sterility, stability or delivery of a separate vial. Those are batch-specific product questions, not automatic extensions of an efficacy result.
Is CJC-1295 authorised in the UK for this use?
No UK marketing authorisation was identified for this use or for a medicine sold under this peptide name. The MHRA products database should be checked for the exact product and presentation. The boundary matters because evidence, authorisation and product quality answer different questions and should not be merged into one conclusion.
What should competitive athletes know?
Growth hormone-releasing factors, including CJC-1295, are prohibited at all times under the WADA S2 category. The boundary matters because evidence, authorisation and product quality answer different questions and should not be merged into one conclusion. Read the cited source and stated scope together before relying on it.
What could change this verdict?
A registered randomised trial measuring validated body composition and function, with a defined formulation, appropriate comparator and long-term safety follow-up. Any update would be dated and recorded through the site correction and version process. The boundary matters because evidence, authorisation and product quality answer different questions and should not be merged into one conclusion.
Continue the investigation